CYP
CYNATA THERAPEUTICS LIMITEDCynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds; and Diabetic Foot Ulcer which has completed phase 1 trial for the treatment of non-healing wounds on the feet/lower limbs. Further, it develops Cohort 1 which has completed Phase 1/2 for the treatment of kidney transplant. Cynata Therapeutics Limited has a license arrangement with Fujifilm corporation. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.
CYP
CYP
CYNATA THERAPEUTICS LIMITED
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease.
Fundamentals
Historical Data27 days
| Date | Short % | Gross Short |
|---|---|---|
| 11 June | — | — |
| 10 June | — | — |
| 9 June | — | — |
| 5 June | — | — |
| 4 June | — | — |
| 3 June | — | — |
| 2 June | — | — |
| 1 June | — | — |
| 29 May | — | — |
| 28 May | — | — |
| 27 May | — | — |
| 26 May | — | — |
Cynata Therapeutics Limited (CYP) Short Interest Summary
Cynata Therapeutics Limited (CYP) currently has 0.00% of its shares sold short (3 thousand shares, worth approximately $1K), based on ASIC short position data reported on 13 May 2026 (T+4 reporting lag). That makes CYP the #661 most shorted stock on the ASX most shorted list. CYP is part of the Health Care sector on the ASX.
Recent CYP Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 13 May 2026 | 0.00% | 0.0M | $0.34 |
| 12 May 2026 | 0.00% | 0.0M | $0.34 |
| 7 May 2026 | 0.00% | 0.0M | $0.31 |
| 6 May 2026 | 0.00% | 0.0M | $0.31 |
CYP Short Selling — Frequently Asked Questions
What is Cynata Therapeutics Limited (CYP)'s current short interest?
Cynata Therapeutics Limited (CYP) currently has a short interest of 0.00% of total shares outstanding. This means 0.00% of CYP's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is CYP heavily shorted on the ASX?
CYP has a relatively low short interest of 0.00%. Short interest below 5% generally suggests limited bearish sentiment from short sellers.
What does short interest mean for CYP investors?
Short interest in CYP shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 0.00%, CYP's short interest is at a low level. See our short squeeze candidates and days to cover analysis for more context.
Where does this CYP short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for CYP.